文献速递前列腺癌

BARCODE1研究与当代前列腺癌筛查试验结果比较

Comparison of Results from the BARCODE1 Study and Contemporary Prostate Cancer Screening Trials.
PubMed 文献 · Eur Urol Oncol · 2025-12-31

本文比较了单臂BARCODE1研究(基于多基因风险评分筛查前列腺癌)与Göteborg-2和ProScreen两项当代大规模筛查试验(使用MRI联合或不联合血液标志物风险分层)的结果。BARCODE1中联合PRS与PSA或MRI使高级别前列腺癌检出较对比试验降低50-75%。作者认为PRS风险区分能力有限,不应在临床实践中采用。

要点

  • BARCODE1单臂设计缺乏对照,限制其结论解释。
  • 标准化后BARCODE1活检人数更多且高级别癌检出更少。
  • PRS联合PSA或MRI较对比试验高级别癌检出降低50-75%。

核心结论

  • 基于PRS的前列腺癌筛查表现劣于当前最佳实践,基于BARCODE1数据不应在临床采用。

研究设计与样本

  • 比较BARCODE1单臂研究(基于PRS筛查)与Göteborg-2和ProScreen两项同期大规模筛查试验(使用MRI联合或不联合PC血液标志物风险分层活检)。

主要发现

  • BARCODE1诊断低级别前列腺癌126例,Göteborg-2为103例,ProScreen为41例。
  • BARCODE1检出高级别前列腺癌155例,Göteborg-2为178例,ProScreen为165例。
  • BARCODE1中联合PRS与PSA或MRI使高级别前列腺癌检出较Göteborg-2和ProScreen降低50-75%。

临床怎么用

  • 基于BARCODE1数据,PRS筛查不应在临床实践中采用。

局限性

  • BARCODE1缺乏对照臂,限制其发现的可解释性;PRS风险区分能力有限,无法优先检出侵袭性疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Polygenic risk scores (PRSs) have generated considerable interest as a means of personalizing prostate cancer (PC) screening by stratifying individuals according to their genetic risk. The single-arm BARCODE1 study recently showed that PRS-based screening detected more PCs than prostate-specific antigen (PSA) testing or magnetic resonance imaging (MRI). The absence of a comparator arm limits the interpretability of this finding. We compared outcomes from BARCODE1 with those from two contemporaneous, large-scale screening trials-Göteborg-2 and ProScreen-that used MRI with or without a PC blood marker to risk-stratify men for biopsy. When standardized to 10 000 men tested, BARCODE1 biopsied more men (704 vs 386 and 338), diagnosed more low-grade PCs (126 vs 103 and 41), and detected fewer high-grade PCs (155 vs 178 and 165) versus Göteborg-2 and ProScreen. Combining PRS with PSA or MRI in BARCODE1 reduced the detection of high-grade PCs by 50-75% in comparison to Göteborg-2 and ProScreen. These findings reflect the limited risk discrimination of PRSs and their inability, unlike MRI and blood-based markers, to preferentially detect aggressive disease. PRS-based PC screening underperforms relative to current best practice and, on the basis of BARCODE1 data, should not be adopted in clinical practice.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Sud A, McNeill A, Vickers AJ, et al. Comparison of Results from the BARCODE1 Study and Contemporary Prostate Cancer Screening Trials. Eur Urol Oncol. 2025. PMID: 41478782. doi:10.1016/j.euo.2025.12.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。